Q-omics provides the consensus-scored ABHD17AP6 profile across patient tissues and cancer cell-line models. ABHD17AP6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, ABHD17AP6 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, ABHD17AP6 RNA expression shows 10,734 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, KIRC, and THYM as cancer lineages where ABHD17AP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD17AP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD17AP6 survival associations across molecular data types. ABHD17AP6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD17AP6 RNA expression–survival associations across cancer types. High ABHD17AP6 expression shows unfavorable associations in LGG, COAD and KIRP, but favorable associations in ESCA, UCS and SKCM. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify ESCA as the clearest survival context for ABHD17AP6 RNA expression.
This table summarizes ABHD17AP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ABHD17AP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD17AP6 shows lower tumor expression in READ, UCEC, COAD, BLCA and LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher ABHD17AP6 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p < 0.001).
This table shows molecular features associated with ABHD17AP6 in patient tissues and cancer cell lines. In patient samples, ABHD17AP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
